Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


  • Sort by Date
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • France, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in France

    November 1, 2012
    Find out more
  • Germany, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries

    November 1, 2012
    Find out more
  • Italy, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries

    November 1, 2012
    Find out more
  • Spain, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Spain; incidence and prevalence figures are compared with those of the Benelux countries

    November 1, 2012
    Find out more
  • United Kingdom, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in the United Kingdom (U.K.); incidence and prevalence figures are compared with those of the Benelux countries

    December 3, 2012
    Find out more
  • Germany, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries

    December 3, 2012
    Find out more
  • Italy, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries

    December 3, 2012
    Find out more
  • Spain, Neurological Market Opportunities: Disease Incidence and Prevalence, And Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Spain

    December 3, 2012
    Find out more
  • United States, Cardiovascular Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the prevalence and number of hospital discharges in the UnitedStates (U.S.) as well as the surgical procedure volumes for selected cardiovascular/thoracic diseases/disorders.

    January 1, 2013
    Find out more
  • United States, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected musculoskeletal diseases/disorders.

    January 1, 2013
    Find out more
  • United States, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected neurological diseases/disorders.

    January 1, 2013
    Find out more
  • U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators

    $3,750.00

    The scope of this report includes tissue-engineered skin replacements and substitutes (i.e., epidermal equivalents, dermal equivalents, and multilayer equivalents) and active wound repair modulators.

    February 1, 2013
    Find out more
  • Current and Emerging U.S. Markets for Myocardial Revascularization, Repair, and Regeneration Products and Therapies

    $4,750.00

    Approximately 16.3 million adults in the United States (U.S.) suffer from coronaryheart disease (CHD), a type of cardiovascular disease that is associated with areduction in blood flow through the vasculature of the heart (ischemic heart disease).

    March 1, 2013
    Find out more
  • U.S. Markets for Diagnostic Oncology-Related X-Ray-Based Imaging Products

    $3,750.00

    Discoveries in molecular medicine in recent years have allowed researchers to study the genetic/chromosomal alterations that trigger the transformation of normal cells into malignant cells, which ultimately has led to the understanding that cancer—of which there are more than 100 forms—is a disease of the cellular genome.

    March 1, 2013
    Find out more
  • U.S. Markets for Compression Therapy and Pressure Reduction and Relief Products Used for Wound Management

    $3,750.00

    The scope of this report includes compression therapy products (e.g., compression bandages, compression stockings, and pneumatic compression devices) and pressure reduction and relief products (e.g., specialty/integrated beds, mattress replacements, and mattress overlays).

    April 1, 2013
    Find out more
  • U.S. Benign Uterine Conditions Therapy Systems Market

    $3,750.00

    This report presents an overview of the most common types of treatment for the benign uterine conditions of menorrhagia and uterine fibroids/polyps; among these therapies are dilation and curettage, hysterectomy, hysteroscopy, and myomectomy. Market and competitive analyses for the medical devices used in these treatments also are presented.

    May 1, 2013
    Find out more
  • U.S. Markets for Orthopedic Biomaterials for Bone Repair and Regeneration

    $3,750.00

    The United States (U.S.) market for orthopedic biomaterials for bone repair and regeneration, as covered by the scope of this report

    May 1, 2013
    Find out more
  • European Markets for Prosthetic Vascular Grafts

    $3,850.00

    Prosthetic vascular grafts, made of synthetic or biological materials, are used to bypass or replace segments of blood vessels in kidney failure patients requiring hemodialysis access as well as those undergoing treatment for aneurysms or vascular occlusions.

    July 1, 2013
    Find out more
  • U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration

    $3,750.00

    The United States (U.S.) market for orthopedic biomaterials, as covered by the scope of this report, comprises bioresorbable fixation devices, visco supplementation products, cartilage repair and regeneration technologies.

    July 1, 2013
    Find out more
  • France, Surgical Procedure Volumes

    $4,850.00

    This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the EU country of France.

    August 1, 2013
    Find out more
  • Women’s Health: Trends and Opportunities in the U.S. Osteoporosis Management Market

    $3,750.00

    This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products.

    September 2, 2013
    Find out more
  • Women’s Health: U.S. Markets for Reproductive Management Products

    $3,750.00

    This report presents market and competitive analyses for selected leading contraceptive and fertility products as well as an overview of the most common types of contraceptives and fertility drugs/treatments available to women in the United States (U.S.) for reproductive management.

    September 2, 2013
    Find out more
  • Germany, Surgical Procedure Volumes

    $4,850.00

    This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Germany.

    October 1, 2013
    Find out more
  • U.S. Markets, Trends, and Opportunities in Patient Monitoring Products

    $4,750.00

    The intensity and high acuity of the critical care environment, combined with the shortage of experienced registered nurses, means that noninvasive and minimally invasive patient monitoring products will be in great demand during the forecast period covered by this report.

    November 1, 2013
    Find out more
  • Spain, Surgical Procedure Volumes

    $4,850.00

    This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Spain.

    November 1, 2013
    Find out more
  • Psychiatry KOL Insight Interview

    $599.00

    At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)

    January 24, 2014
    Find out more
  • Selexipag for Pulmonary Arterial Hypertension

    $89.00

    Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.

    February 1, 2014
    Find out more
  • Palbociclib for Breast Cancer

    $89.00

    Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

    February 1, 2014
    Find out more
  • NASH KOL Insight Interview #1

    $599.00

    The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold

    February 20, 2014
    Find out more
  • Macitenan for Pulmonary Arterial Hypertension

    $89.00

    Macitentan is a novel dual endothelin receptor antagonist (ERA)

    showing sustained receptor occupancy

    March 1, 2014
    Find out more
  • NASH KOL Insight Interview #2

    $599.00

    KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]

    March 4, 2014
    Find out more
  • Seizure Pulse Survey

    $599.00

    Eslicarbazepine has been approved in ex-US markets including the EU for years.

    We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.

    March 25, 2014
    Find out more
  • Aromatase Resistance and Palbociclib for Breast Cancer

    $89.00

    These pathways can be targeted either at the cell surface receptor

    level or their downstream signaling cascades. Currently, everolimus in combination with

    exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

    HDAC inhibitors have also shown promising results For innate resistance, the combination of

    fulvestrant and AI in the front line setting represents a new treatment option, particularly for

    patients who present with de novo metastatic disease.

    April 1, 2014
    Find out more
  • U.S. Ophthalmic Surgical Systems Market, April 2014

    $3,750.00

    This report discusses common ophthalmic diseases/disorders, prevalence, estimated U.S. procedure volumes, leading energy-based (laser and phacoemulsification, or “phaco”) ophthalmic surgical systems and their features, and novel technologies. A detailed U.S. market analysis, competitive analysis, and company profiles of selected U.S. competitors are also provided.

    April 1, 2014
    Find out more
  • Congestive Heart Failure Pulse Survey

    $599.00

    The study was just closed early, as LCZ696 increased time to first occurrence of either

    cardiovascular death or heart failure hospitalization, though details have not been released.

    We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different

    assumptions about what the study found.

    April 1, 2014
    Find out more
  • Midostaurin

    Read More

    Midostaurin is a multiple kinase inhibitor, which interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML.

    April 22, 2014
    Find out more
  • Volasertib

    Read More

    Volasertib is a polo-like kinase (Plk) inhibitor being developed by Boehringer Ingelheim for the treatment of AML.

    April 22, 2014
    Find out more
  • Breast Cancer Pulse Survey

    $599.00

    Drugs and drug candidates discussed:

    palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor

    April 23, 2014
    Find out more
  • Post-EASL KOL Insight Interview

    $599.00

    The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
    London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
    soon-to-be approved, direct-acting antivirals for Hepatitis C.

     

    May 6, 2014
    Find out more
  • Ovarian Cancer Pulse Survey

    $599.00

    Diagnostics/diagnostic techniques discussed:

    etarfolatide/folic acid, BRCA mutation testing

    May 7, 2014
    Find out more
  • Breast Cancer KOL Insight Interview

    $599.00

    Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent
    change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.

    May 8, 2014
    Find out more
  • Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

    $599.00

    Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.

    May 13, 2014
    Find out more
  • Flolan

    Read More

    In 1995, GlaxoSmithKline’s Flolan (epoprostenol) became the first therapy to be specifically approved for the orphan disease of pulmonary arterial hypertension (PAH).

    June 25, 2014
    Find out more
  • Dyslipidemia KOL Insight Interview #1

    $599.00

    Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data

    July 25, 2014
    Find out more
  • Dyslipidemia KOL Insight Interview #2

    $599.00

    Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.

    July 28, 2014
    Find out more
Page 1 of 29
Page 1 of 29123›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top